ACHC vs PTRN: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

ACHC and PTRN are similarly sized, but ACHC trades noticeably cheaper on forward earnings (18.83x vs 25.19x): the market is paying up for PTRN's profile and pricing ACHC more conservatively, or for faster growth. Which you prefer comes down to the drivers you believe, and whether adding either over-concentrates what you already own.

ACHC vs PTRN: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricACHCPTRNWhat it tells you
Market cap$3.57B$3.53BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E18.8325.19Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Price vs 52-week range95% of range53% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book1.725.35How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Reading it: ACHC is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

Before you buy: how ACHC and PTRN affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ACHC and PTRN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ACHC and PTRN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Acadia Healthcare (ACHC) do?

Acadia Healthcare (NASDAQ: ACHC) is the leading pure-play behavioral healthcare provider in the United States, operating roughly 277 facilities with more than 12,500 licensed beds across about 40 states and Puerto Rico as of the end of 2025. Its business spans four service lines: acute inpatient psychiatric hospitals (its largest and fastest-growing segment), specialty treatment facilities, comprehensive treatment centers for opioid-use disorder, and residential treatment centers. Revenue is heavily tied to government payors, with Medicaid at roughly 58 percent, commercial at about 25 percent, and Medicare near 14 percent, and no single facility contributing more than about 4 percent of total revenue.

Full ACHC guide

What does Pattern Group Inc. (PTRN) do?

Pattern Group Inc. helps consumer brands sell on global ecommerce marketplaces, and it does so mostly by taking title to the goods. Brands sell products to Pattern at agreed prices, Pattern lists and sells them to consumers on more than 70 marketplaces including Amazon, Walmart.com, Target.com, TikTok Shop, eBay, Tmall, JD and Mercado Libre, and Pattern keeps the spread after marketplace commissions, advertising and fulfillment. The company works with more than 250 brands across health and wellness, beauty and personal care, home, pet, sports and consumer electronics, sells into more than 100 countries, and says it has accumulated over 91 trillion ecommerce data points feeding the machine learning models that set prices, bids and inventory forecasts. Around 510 engineers and data scientists support the platform, which the company markets as Pattern Intelligence (or Pi) following a May 2026 launch, and it holds 44 patents issued or pending. Pattern listed on Nasdaq on September 19, 2025 at $14.00 per share and reports in U.S. dollars.

Full PTRN guide

ACHC vs PTRN: how do they differ?

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

  • ACHC drivers: Structural demand for behavioral health; Bed expansion and de novo growth.
  • PTRN drivers: Growth from brands already on the platform; Diversification away from Amazon and the United States.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Legal and regulatory exposure is the defining risk. For PTRN, the concentration risk is stated plainly in Pattern's own filings: 93% of 2025 revenue came from consumer product sales on Amazon, the relationship runs on non-negotiable click-through terms that either side can end at will, and the company discloses that it has previously experienced account suspensions, payment-term changes and higher fulfillment fees.

ACHC or PTRN: which should you pick?

Pick ACHC if you believe its drivers more; PTRN if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ACHC and PTRN guides.

ACHC vs PTRN: the full fundamentals

ACHC. Acadia closed at ~$30.52 on October 16, 2026, up ~114% year to date after the stock rebounded from a 52-week low near $11.43. It trades at about 16.5x forward EPS and ~10.3x EV/EBITDA, with analysts' mean target near $33.79 across 14 firms, so the market is still discounting legal and reimbursement uncertainty. Reported earnings remain depressed by the late-2025 impairment, legal and interest costs even as adjusted metrics grow.

PTRN. All figures are in U.S. dollars. At roughly 1.0x trailing sales Pattern screens cheaper than it did in August, but most of its revenue is resold merchandise rather than software, so the sales multiple is not comparable to marketplace-software peers; enterprise value of roughly $2.7 billion against guided 2026 adjusted EBITDA near $212 million (about 13x) is the more useful anchor. Trailing GAAP figures remain distorted by the one-time IPO stock compensation charge from the third quarter of 2025, so the forward P/E of about 22x on 2027 consensus EPS of ~$0.79 says more about how the market prices the business today.

Headline figures (approximate, October 2026): ACHC shows revenue (ttm) ~$3.37B (Q2 2026 ~$866M), 2026 revenue guidance (spring) ~$3.37B to $3.45B, q2 2026 adj. eps ~$0.38 (vs ~$0.35 est.), net income (ttm) ~-$1.13B (late-2025 impairment); PTRN shows revenue (ttm through q2 2026) ~$3.01B; Q2 2026 revenue growth ~47% year over year, q2 2026 results Revenue ~$877M, net income ~$27.5M, EPS ~$0.16 vs ~$0.12 consensus, margins (ttm) Gross ~44%, operating ~4.1%, net ~0.9% (depressed by Q3 2025 IPO stock compensation), fy2026 outlook Company guidance ~$3.42B to ~$3.46B revenue and ~$211M to ~$213M adjusted EBITDA; consensus ~$3.44B revenue, EPS ~$0.63.

The bottom line: ACHC vs PTRN

ACHC and PTRN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ACHC and PTRN exposure against your real portfolio. It is not an investment adviser.

Wondering how ACHC or PTRN fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Acadia Healthcare

Ask Walnut's AI anything about ACHC and see how it fits what you own.

FAQ

What is the difference between ACHC and PTRN?

+

Acadia Healthcare (NASDAQ: ACHC) is the leading pure-play behavioral healthcare provider in the United States, operating roughly 277 facilities with more than 12,500 licensed beds across about 40 states and Puerto Rico as of the end of 2025. Pattern Group Inc. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is ACHC or PTRN the better stock?

+

Neither is universally better; they suit different views and risk levels. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, ACHC or PTRN?

+

On forward P/E (as of November 2026), ACHC trades at 18.83x and PTRN at 25.19x, so ACHC is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both ACHC and PTRN?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of ACHC vs PTRN?

+

ACHC: Legal and regulatory exposure is the defining risk. Acadia agreed to pay $179 million to settle a securities class action tied to prior disclosures, faces a September 2024 DOJ Criminal Division grand jury subpoena related to its acute admissions, length of stay, and billing practices, and disclosed a sharp rise in patient-related litigation expense (roughly $116 million projected for 2025 versus $54 million in 2024). A 2024 New York Times investigation alleged patients were improperly detained, and a May 2026 California jury awarded $105 million in a retaliatory-termination case. The company also carries meaningful leverage, with total debt around $2.6 billion against ~$171 million of cash at June 30, 2026, and took a large goodwill impairment in late 2025 that left trailing twelve-month net income at about -$1.1 billion. Free cash flow over the trailing year was negative (about -$105 million) as capital spending on new beds outran operating cash flow of ~$211 million. Heavy Medicaid and Medicare reliance leaves it exposed to reimbursement-rate and policy changes. PTRN: The concentration risk is stated plainly in Pattern's own filings: 93% of 2025 revenue came from consumer product sales on Amazon, the relationship runs on non-negotiable click-through terms that either side can end at will, and the company discloses that it has previously experienced account suspensions, payment-term changes and higher fulfillment fees. Because Pattern buys inventory rather than charging a fee, it absorbs demand-forecast errors, price competition and obsolescence on a net margin of roughly 3%, and it booked an $8.5 million inventory reserve at the end of 2025. Supplier concentration compounds this, with two brand partners each representing 17% of 2025 inventory purchases, and tariffs or shifts in United States and China trade policy sit directly on the cost of goods. Governance is a separate consideration: Pattern is a controlled company under Nasdaq rules, the co-founders held about 86.5% of voting power after the IPO through 20-vote Series B shares, and the March 2026 lock-up expiry plus a June 2026 secondary offering by a selling stockholder have already added supply to a thin float. Trailing GAAP earnings are also distorted downward by roughly $59 million of IPO-related stock compensation recognised in the third quarter of 2025, which makes any trailing P/E on PTRN close to meaningless. On a trailing twelve-month basis Yahoo Finance shows a net loss of about $132 million and a 0.9% profit margin, again because of that third-quarter 2025 charge, which rolls out of the trailing figures once the September 2026 quarter is reported. Sentiment has also proved fragile: the stock fell about 35% between mid-July and mid-October 2026 without a change in reported fundamentals.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell ACHC or PTRN; figures are approximate and dated (as of November 2026). Verify current data before investing.